{"title": "Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2", "doi": "10.1101/2020.03.17.20036640", "citation_id": "2020.03.17.20036640v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.17.20036640", "abstract": "<p>The WHO has declared SARS-CoV-2 outbreak a public health emergency of international concern. However, to date, there was hardly any study in characterizing the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. In this study, we collected blood from COVID-19 patients who have recently become virus-free and therefore were discharged, and analyzed their SARS-CoV-2-specific antibody and T cell responses. We observed SARS-CoV-2-specific humoral and cellular immunity in the patients. Both were detected in newly discharged patients, suggesting both participate in immune-mediated protection to viral infection. However, follow-up patients (2 weeks post discharge) exhibited high titers of IgG antibodies, but with low levels of virus-specific T cells, suggesting that they may enter a quiescent state. Our work has thus provided a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It has also implications in designing an effective vaccine to protect and treat SARS-CoV-2 infection.</p>", "twitter_description": "The WHO has declared SARS-CoV-2 outbreak a public health emergency of international concern. However, to date, there was hardly any study in characterizing the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. In this study, we collected blood from COVID-19 patients who have recently become virus-free and therefore were discharged, and analyzed their SARS-CoV-2-specific antibody and T cell responses. We observed SARS-CoV-2-specific humoral and cellular immunity in the patients. Both were detected in newly discharged patients, suggesting both participate in immune-mediated protection to viral infection. However, follow-up patients (2 weeks post discharge) exhibited high titers of IgG antibodies, but with low levels of virus-specific T cells, suggesting that they may enter a quiescent state. Our work has thus provided a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It has also implications in designing an effective vaccine to protect and treat SARS-CoV-2 infection.\n\n### Competing Interest Statement\n\nLN, YF, WP and CD have filed a provisional patent on the methodology of detecting SARS-CoV-2-specific antibody responses.\n\n### Funding Statement\n\nThis work was supported in part by grants from Natural Science Foundation of China (NSFC, Grant No. 31991173 to CD), National key research (Grant No. 2016YFC130390 to LN) and an award from Zhejiang University Foundation (to CD).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data referred to in the manuscript are available.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20036640.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.17.20036640v1", "access_rights": "restricted", "authors": ["Chen Dong", "Ling Ni", "Fang Ye", "Meng-Li Chen", "Yu Feng", "Yong-Qiang Deng", "Hui Zhao", "Peng Wei", "Jiwan Ge", "Xiaoli Li", "Lin Sun", "Pengzhi Wang", "Peng Liang", "Han Guo", "Xinquan Wang", "Cheng-Feng Qin", "Fang Chen"]}